SCHEMBL4766574

SCHEMBL4766574

CC(C)NCCCCS(=O)(=O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.44
CA2 P00918 3/20 0.44
CA9 Q16790 3/20 0.44
CA12 O43570 2/20 0.44
CA3 P07451 2/20 0.44
CA4 P22748 2/20 0.44
CA6 P23280 2/20 0.44
CA5A P35218 2/20 0.44
CA7 P43166 2/20 0.44
CA13 Q8N1Q1 2/20 0.44
CA14 Q9ULX7 2/20 0.44
CA5B Q9Y2D0 2/20 0.44
PKM P14618 1/20 0.41
ALDH1A1 P00352 5/20 0.41
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP8 P22894 1/20 0.41
MMP13 P45452 1/20 0.41
KMT2A Q03164 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10409374 0.90 CA1 (0.47) CA1CA2CA9CA12CA3
SCHEMBL4770148 0.81 GAA (0.47) CA1CA2CA9CA12ALDH1A1
SCHEMBL10682145 0.80 HDAC1 (0.49) PKMALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL10738787 0.80 MEN1 (0.62) CA1CA2CA9CA12CA3
SCHEMBL9383251 0.79 ALDH1A1 (0.53) ALDH1A1KMT2AMAPTCHRM2
SCHEMBL10689278 0.79 HDAC1 (0.51) PKMALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL21157752 0.79 CA9 (0.46) CA1CA2CA9CA12CA3
Hydrochloric Acid SCHEMBL10687757 0.79 HDAC1 (0.48) PKMALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL7019690 0.78 ALDH1A1 (0.32) ALDH1A1MAPTCYP3A4CYP2C9CYP2C19
SCHEMBL11134832 0.77 ALDH1A1 (0.56) CA1CA2CA9CA12CA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303496-B9 PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2008-03-19 EP disclosed
EP-1303496-B1 PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2007-09-12 EP disclosed
EP-1406876-B1 2-ANILINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS ASTRAZENECA AB (SE) 2006-12-27 EP disclosed
US-6939872-B2 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors ASTRAZENECA AB (SE) 2005-09-06 US disclosed
US-6908920-B2 Pyrimidine derivatives ASTRAZENECA AB (SE) 2005-06-21 US disclosed
US-20040198757-A1 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors ASTRAZENECA AB (SE) 2004-10-07 US disclosed
US-20030216406-A1 Pyrimidine derivatives ASTRAZENECA AB (SE) 2003-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198757-A1 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors CCNT1, CCNI, CDK2 CA1 2019/4885CA2 1307/4885CA9 2990/4885
US-20030216406-A1 Pyrimidine derivatives TYMP, TYMS, CCNT1 CA1 3010/4885CA2 2742/4885CA9 3548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.